Peripartum Aortic Dissection Risk Factors Examined in Marfan Sx

Share this content:
Peripartum Aortic Dissection Risk Factors Examined in Marfan Sx
Peripartum Aortic Dissection Risk Factors Examined in Marfan Sx

WEDNESDAY, Dec. 21, 2016 (HealthDay News) -- Pregnant patients with Marfan syndrome, particularly those with a dilating aortic root, are at high risk of aortic dissection during and following pregnancy, according to a study published in the Jan. 1 issue of The American Journal of Cardiology.

Rafael Kuperstein, M.D., from the Sheba Medical Center in Tel Hashomer, Israel, and colleagues examined the risk for aortic dissection and pregnancy outcome in patients with Marfan syndrome. Women were offered β-blockers, which were titrated by blood pressure and heart rate. Patients with aortic root dilation of ≥40 mm were considered high risk. Thirty-one pregnancies in 19 women with Marfan syndrome were followed.

The researchers found that eight pregnancies occurred in patients with a dilated aortic root; β-blocker treatment was used by 21 patients. Two cases of postpartum aortic dissection occurred (6.5 percent): one type A dissection in a patient with a dilated aortic root who declined β-blockers and one type B dissection. There was a significant association for increasing aortic root diameter with later aortic dissection (two of six versus zero of 21; P = 0.04). There were no maternal deaths. High-risk women with Marfan syndrome gave birth by cesarean section, while the mode of delivery was obstetric indication in the non-high-risk group.

"Pregnant patients with Marfan syndrome, especially those with a dilating aortic root, are at high risk of aortic dissection, even with tight control of blood pressure and heart rate," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »